Why Alnylam Pharmaceuticals Rose 12.7% in November
In response to the company sharing a slew of positive developments with investors, shares of Alnylam Pharmaceuticals (NASDAQ: ALNY), a clinical-stage biotech focused on RNAi therapies, jumped 13% in November according to data from S&P Global Market Intelligence.
Here's a review of the key announcements made during the month:
Given the news, it isn't hard to figure out why investors had yet another profitable month.
Source: Fool.com
Alnylam Pharmace. Stock
€140.00
5.670%
With 36 Buy predictions and not a single Sell prediction Alnylam Pharmace. is an absolute favorite of our community.
With a target price of 228 € there is a hugely positive potential of 62.86% for Alnylam Pharmace. compared to the current price of 140.0 €.
